Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IgE Fc region |
Clinical data | |
Pronunciation | /ˌoʊməˈlɪzumæb/ OH-mə-LI-zoo-mab |
Trade names | Xolair |
Biosimilars | Omlyclo[1][2] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603031 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 26 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6450H9916N1714O2023S38 |
Molar mass | 145058.53 g·mol−1 |
(what is this?) (verify) |
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives),[10][11] and immunoglobulin E-mediated food allergy.[12]
Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.[13][14] Its primary adverse effect is anaphylaxis.
In 1987, Tanox filed its first patent application on the anti-IgE drug candidates. It took until 2003 in the United States until omalizumab was approved, and in Europe until 2005 for moderate to severe persistent asthma and severe chronic rhinosinusitis with nasal polyps. In February 2024, the FDA approved it also to treat severe food allergy.
Omlyclo EPAR
was invoked but never defined (see the help page).Omlyclo EU PI
was invoked but never defined (see the help page).FDA PR 20240216
was invoked but never defined (see the help page).